Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
CAS RN: 154361-50-9 | Product Number: C2878
Capecitabine
Purity: >98.0%(T)(HPLC)
- 5'-Deoxy-5-fluoro-N4-[(pentyloxy)carbonyl]cytidine
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | C2878 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__5H__2__2FN__3O__6 = 359.35 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 154361-50-9 |
| Reaxys Registry Number | 8583270 |
| PubChem Substance ID | 253661933 |
| Merck Index (14) | 1754 |
| MDL Number | MFCD00930626 |
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | +96.0 to +100.0 deg(C=1, MeOH) |
| NMR | confirm to structure |
| Melting Point | 123 °C(dec.) |
| Specific Rotation | 98° (C=1,MeOH) |
| Solubility in water | Slightly soluble |
| Degree of solubility in water | 26 g/l 20 °C |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H360 : May damage fertility or the unborn child. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. |
| RTECS# | HA3852500 |
| HS Number | 2934999090 |
References
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
- Capecitabine: preclinical pharmacology studies (a review)
- Clinical pharmacokinetics of capecitabine (a review)
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Capecitabine: an overview of the side effects and their management (a review)
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.